News
KTTA
7.11
+1.55%
0.11
Weekly Report: what happened at KTTA last week (0429-0503)?
Weekly Report · 2d ago
Pasithea Therapeutics Announces PAS-004 Abstract Accepted For Poster Presentation At 2024 ASCO Annual Meeting
Pasithea Therapeutics Corp. Is developing PAS-004, a next-generation macrocyclic MEK inhibitor for the treatment of neurofibromatosis type 1 (NF1) The company has accepted an abstract for poster presentation at the American Society of Cancer Oncology in Chicago. The company is the first to enter human clinical trials for Pas-004.
Benzinga · 04/29 12:14
Weekly Report: what happened at KTTA last week (0422-0426)?
Weekly Report · 04/29 10:30
Pasithea Therapeutics Announces The First Cohort Has Completed The Initial Dosing In Its Phase 1 Trial Evaluating PAS-004 In RAS, NF1 And RAF Mutated Cancers
Pasithea Therapeutics Corp. Is developing PAS-004, a next-generation macrocyclic MEK inhibitor for the treatment of neurofibromatosis type 1 (NF1) The first cohort of 3 patients have commenced dosing in a Phase 1 clinical trial in patients with MAPK pathway driven advanced solid tumors. The company is the first to enter human clinical trials for the first time. Pas-004 has received orphan-drug designation from the FDA.
Benzinga · 04/24 12:05
Weekly Report: what happened at KTTA last week (0415-0419)?
Weekly Report · 04/22 10:24
Weekly Report: what happened at KTTA last week (0408-0412)?
Weekly Report · 04/15 10:18
Weekly Report: what happened at KTTA last week (0401-0405)?
Weekly Report · 04/08 10:21
Weekly Report: what happened at KTTA last week (0325-0329)?
Weekly Report · 04/01 10:20
Weekly Report: what happened at KTTA last week (0318-0322)?
Weekly Report · 03/25 10:22
Weekly Report: what happened at KTTA last week (0311-0315)?
Weekly Report · 03/18 10:21
Weekly Report: what happened at KTTA last week (0304-0308)?
Weekly Report · 03/11 10:19
Weekly Report: what happened at KTTA last week (0226-0301)?
Weekly Report · 03/04 10:21
Weekly Report: what happened at KTTA last week (0219-0223)?
Weekly Report · 02/26 10:28
Weekly Report: what happened at KTTA last week (0212-0216)?
Weekly Report · 02/19 10:29
Pasithea Therapeutics Announces Opening Of Enrollment In The U.S. For Its Phase 1 Trial Of PAS-004
Pasithea Therapeutics Corp. Announces activation of four U.S. Sites for Phase 1 clinical trial of PAS-004 to evaluate safety, dose, key biomarker data and preliminary efficacy. The company is developing a next-generation macrocyclic MEK inhibitor for the treatment of neurofibromatosis type 1. Three additional clinical trial sites in Eastern Europe are expected to open in the coming months. Preliminary interim data expected in 2H 2024.
Benzinga · 02/13 12:59
Weekly Report: what happened at KTTA last week (0205-0209)?
Weekly Report · 02/12 10:23
Weekly Report: what happened at KTTA last week (0129-0202)?
Weekly Report · 02/05 10:28
Weekly Report: what happened at KTTA last week (0122-0126)?
Weekly Report · 01/29 10:21
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Pre-market stock movers are worth checking out on the final day of trading this week. Aclarion (NASDAQ:ACON) stock is rocketing more than 79% alongside heavy pre-market trading. Public offerings, an earnings report and more are moving stocks today.
Investorplace · 01/26 12:35
Weekly Report: what happened at KTTA last week (0115-0119)?
Weekly Report · 01/22 10:24
More
Webull provides a variety of real-time KTTA stock news. You can receive the latest news about Pasithea Therapeutics Corp through multiple platforms. This information may help you make smarter investment decisions.
About KTTA
Pasithea Therapeutics Corp. is a biotechnology company focused on the discovery, research and development of treatments for central nervous system (CNS) disorders and other diseases. The Company is advancing a pipeline of three therapeutic product candidates, with a focus on its lead product candidate, PAS-004, a macrocyclic mitogen-activated protein kinase, or MEK inhibitor. PAS-004 is a small molecule allosteric inhibitor of MEK 1 and 2 (MEK 1/2) for potential use in the treatment of a range of RASopathies, including neurofibromatosis type 1 (NF1) and a number of oncology indications, among others. Its remaining two programs, PAS-001 and PAS-003, are in the earlier stages of development and are based on novel targets for the treatment of CNS disorders that it believes address limitations in the treatment paradigm of the indications it plans to address, which are amyotrophic lateral sclerosis (ALS) for its PAS-003 program, and schizophrenia for its PAS-001 program.